In Re Pharmaceutical Industry Average Wholesale Price Litigation

498 F. Supp. 2d 389, 68 Fed. R. Serv. 3d 783, 2007 U.S. Dist. LEXIS 51343, 2007 WL 2058731
District Court, D. Massachusetts·Decided July 17, 2007·No. MDL No. 1456, Master File No. 01-12257-PBS, Civil Action No. 05-11084-PBS·Published·Cited by 12 cases

Opinion

MEMORANDUM AND ORDER

SARIS, District Judge.

INTRODUCTION

The United States brings this action under the False Claims Act, 31 U.S.C. § 3729 et seq., seeking to recover losses to the Medicare and Medicaid programs caused by allegedly fraudulent average wholesale prices for generic drugs reported by defendants Dey, Inc., Dey L.P., Inc., and Dey L.P. (collectively “Dey”).

Relator Ven-A-Care filed its qui tarn complaint against Dey in the Southern District of Florida on August 13, 1997. Nine years later, after seeking numerous sixty day extensions from the court, the government elected to intervene. On August 24, 2006, the government filed a “complaint-in-intervention” against the defendants, which was unsealed on September 7, 2006, and served Dey with this unsealed complaint. 1 The factual basis for the complaint is set forth in this Court’s prior opinion in United States ex rel. Ven-A-Care of the Florida Keys, Inc. v. Abbott Labs., Inc., 491 F Supp.2d 12, 15-17 *393 (D.Mass.2007), with which the Court assumes familiarity.

Among other things, Dey argues that all causes of action accruing in connection with claims submitted for payment more than 6 years before the government intervened are barred by the statute of limitations, 31 U.S.C. § 3731(b)(1). Citing United States v. The Baylor Univ. Med. Ctr., 469 F.3d 263, 268 (2d Cir.2006) (“Baylor ”), Dey argues that the action is deemed to have been commenced against Dey for statute of limitations purposes when the complaint-in-intervention was filed by the government on August 24, 2006.

After oral argument, the Court ALLOWS, in part, and DENIES, in part, Dey’s motion to dismiss.

PROCEDURAL BACKGROUND 2

Relator filed its initial complaint in 1995, and an amended complaint against Dey on August 13, 1997, in the United States District Court for the Southern District of Florida. Relator filed a separate complaint against Dey in this district on April 10, 2000. On December 22, 2004, the United States and relator moved to sever and transfer the claims against Dey in Florida to Massachusetts. Those claims were transferred to this district and assigned Case No. 05-11084. On June 26, 2006, in response to the United States’ and relator’s request, the related claims originally filed against Dey in the District of Massachusetts were severed from the remainder of that case and consolidated with the claims transferred from Florida. On August 23, 2006, this case finally saw the light of Dey when the United States filed its notice of intervention and complaint-in-intervention in the consolidated case. The complaint was formally unsealed on September 7, 2006. On October 31, 2006, relator Ven-A-Care filed an amended complaint, which adopted the United States’ complaint. On November 20, 2006, the case was consolidated with this Court’s Average Wholesale Price Multi-District Litigation (“MDL”) proceeding.

DISCUSSION

A. The FCA

The FCA is “intended to reach all types of fraud, without qualification, that might result in financial loss to the Government.” United States v. Neifert-White Co., 390 U.S. 228, 232, 88 S.Ct. 959, 19 L.Ed.2d 1061 (1968). It permits private entities, called relators, to enforce the civil provisions of the act on behalf of the government. See 31 U.S.C. § 3730(b). When a relator files suit, the FCA provides that the “action shall be brought in the name of the Government.” 31 U.S.C. § 3730(b)(1). Consequently, “[t]he relator in a qui tam FCA action, while having a stake in the lawsuit, represents the interests of the United States.” United States ex rel. Rockefeller v. Westinghouse Elec. Co., 274 F.Supp.2d 10, 16 (D.D.C.2003).

When a private relator, such as Ven-A-Care, brings a claim' against a defendant, the statute mandates that a “copy of the complaint and written disclosure of substantially all material evidence and information the person possesses shall be served on the Government” under Fed. R.Civ.P. 4(d)(4). See 31 U.S.C. § 3730(b)(2). Furthermore, the FCA requires, “The complaint shall be filed in camera, shall remain under seal for at least 60 days, and shall not be served on *394 the defendant until the court so orders.” Id. This sixty day provision does not limit the number of extensions that the government may obtain in order to investigate the relator’s complaint, provided the government can establish “good cause” before the court presiding over the case. Id.; see also United States v. Stella Perez, 956 F.Supp. 1046, 1052 (D.P.R.1997) (holding that the FCA “imposes a duty of diligence on the part of the government to ascertain facts material to its right of action”).

Ultimately, the government elects either to intervene in the case or to allow the relator to pursue the action alone on behalf of the United States. If the government chooses to intervene in a relator’s suit pursuant to 31 U.S.C. § 3730(b)(4)(A), 3 the FCA provides that “the action shall be conducted by the Government.” This takeover provision dictates, “If the Government proceeds with the action, it shall have the primary responsibility for prosecuting the action, and shall not be bound by an act of the person bringing the action.” See 31 U.S.C. § 3730(c)(1).

A defendant is not required to respond to any qui tarn complaint until 20 days after the complaint is unsealed and served upon it. 31 U.S.C. § 3730(b)(3).

B. Statute of Limitations

Dey moves to dismiss the government’s complaint-intervention on the ground that it is time-barred. The FCA provides:

(b) A civil action under section 3730 [providing a right of action for FCA] may not be brought—

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Pharmaceutical Industry Average Wholesale Price Litigation, 498 F. Supp. 2d 389, 68 Fed. R. Serv. 3d 783, 2007 U.S. Dist. LEXIS 51343, 2007 WL 2058731 (D. Mass. 2007).

498 F. Supp. 2d 389 (In Re Pharmaceutical Industry Average Wholesale Price Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States ex rel. Estate of Gadbois v. Pharmerica Corp.
292 F. Supp. 3d 570 (D. Rhode Island, 2017)
Hayes v. Department of Education
20 F. Supp. 3d 438 (S.D. New York, 2014)
United States ex rel. Vavra v. Kellogg Brown & Root, Inc.
903 F. Supp. 2d 473 (E.D. Texas, 2011)
United States v. Actavis Mid Atlantic LLC
659 F. Supp. 2d 262 (D. Massachusetts, 2009)
United States Ex Rel. Deering v. Physiotherapy Associates, Inc.
601 F. Supp. 2d 368 (D. Massachusetts, 2009)
United States Ex Rel. Ramadoss v. Caremark Inc.
586 F. Supp. 2d 668 (W.D. Texas, 2008)
Miller v. Holzmann
563 F. Supp. 2d 54 (District of Columbia, 2008)
In Re Pharm. Indus. Average Wholesale Price Litig.
538 F. Supp. 2d 392 (D. Massachusetts, 2008)